Comprehensive pan-cancer studies that explicitly target PTPN3 have not yet been conducted, and the precise roles that PTPN3 plays in modifying the tumor immune milieu and how that affects immunotherapy have not been thoroughly examined in scientific literature. The gene discussed is PTPN3; the disease is neoplasm.